Precisely.The only strong contention that I have is whether or not reductions in striatal DAT and DA/DOPAC concentrations actually represent profound dopaminergic neurotoxicity. Ricaurte, et al certainly equate these molecular parameters with permanent dopaminergic nerve terminal damage, but that has not yet been adequately shown.
significant reductions in striatal
dopamine concentration, the density of [3H]WIN35,428labeled
DAT sites, the amount of DAT
protein and the number of [3H]DTBZlabeled
VMAT2 sites; quantitative autoradiographic
studies showed that the regional density of [125I]RTI121labeled
DAT sites was comparably
reduced (Fig. 1). A closer examination of regional monoamine data revealed lasting
dopaminergic deficits in the caudate nucleus and putamen of comparable magnitude (44 47
% depletions), while smaller, but significant, deficits (approximately 30 %) were also evident in the nucleus accumbens (Fig. 2a)
The thing is we have no idea if any of this is permanent, or if it even represents "damage."
Last edited:
